Diabetic peripheral neuropathy affects nearly half of people living with diabetes, and it remains one of the harder complications to treat. The approved options for painful diabetic neuropathy manage symptoms rather than the underlying nerve damage, and candidates aimed at the disease process itself have had a difficult path from animal data to patient benefit. At the same time, the metabolic landscape is shifting. GLP-1 receptor agonists and related agents are changing glycemic control across the type II population, and programs are now asking whether those mechanisms, or new ones, can reach the peripheral nerve.
That combination puts more weight on preclinical model selection than it carried a decade ago. Type I and type II diabetes injure nerves through overlapping but distinct routes, the patient populations differ in age, weight, and metabolic profile, and a candidate positioned for one will be tested clinically in patients who look like that group. MD Biosciences runs three models of diabetic neuropathy, each representing a different route into the disease, so that a study can be matched to the population and mechanism a program has in mind.
Streptozotocin ablates pancreatic beta cells and produces a type I diabetic state within days. The model runs in SD rats and C57Bl/6 mice over 11 to 28 days, with induction on day 0, blood glucose confirmed on day 3, and animals included on day 10 based on blood glucose and von Frey testing.
The neuropathy that follows is understood to arise through more than one route. Hyperglycemia damages nerve endings through inflammatory processes and through interference with blood supply, and streptozotocin also acts directly on neurons, with reactive oxygen species mediating elevation of TRPV1 in neurons and dorsal root ganglion exposed to the compound in vitro. The model is fast and is characterized against gabapentin and pregabalin, which is why it serves as a first screen for analgesic and neuroprotective candidates in diabetic neuropathy.
The example data show the dynamic range a study can work with. By day 10 after induction, von Frey withdrawal thresholds fall to roughly a tenth of baseline. Gabapentin given two hours before testing restores them to near baseline from the following day and holds that effect through day 21, while vehicle animals stay at the reduced threshold. Sensory nerve conduction velocity falls by roughly a third at one month after induction, and pregabalin does not restore it, so the conduction endpoint reads something different from the behavioral one. The model also shows a sex difference worth designing around. Female rats respond to hot and cold plate stimulation where males do not, so both sexes are included. Plasma cytokines in male rats show TNF-a and RANTES increased and IL-10 decreased against naive animals, with the same pattern more pronounced in cerebrospinal fluid.
The high fat diet model represents the type II route. C57Bl/6 mice are maintained on a 42 percent kcal diet against a 10 percent kcal control for 11 to 16 weeks, with 14 weeks in the characterization study. Over that period the animals gain weight and become insulin resistant, with blood glucose running above controls and a marked excursion under a glucose challenge, while not reaching the sustained hyperglycemia of the streptozotocin or ZDF models. This makes it the model of choice when the question is what insulin resistance and diet driven metabolic change do to peripheral nerve, which is the biology most type II patients present with.
Mechanical allodynia develops from week 10 onward and does not progress to the hypo-sensitive phase seen in later stage streptozotocin mice, so the model holds a stable hypersensitive state through the treatment window. The electrophysiology readout is the withdrawal reflex evoked by stimulation of the posterior tibial nerve, and in the example data the response amplitude increased and its latency shortened in high fat diet animals compared with controls. Gabapentin and morphine serve as reference compounds.
The Zucker Diabetic Fatty rat develops obese type II diabetes on its own, with no chemical inducer and no dietary manipulation. Over a 13 week study against lean Sprague Dawley controls, ZDF rats reach roughly 70 percent greater body weight, and a glucose tolerance test at day 90 confirms glucose intolerance, with a higher peak than controls and glucose still elevated at two hours. This is the model that pairs obesity with progressive hyperglycemia, which is why it suits candidates positioned on metabolic efficacy alongside a neuropathy endpoint, including GLP-1 based and adjacent anti-diabetic programs.
The sensory phenotype is large and stable. Von Frey thresholds sit roughly 80 percent below controls and hold across the 13 week study. Hot plate latency in ZDF rats falls from baseline to day 90 while control latency rises, and adhesive removal testing shows contact and removal times two to five times longer than controls, reading impaired somatosensory function alongside the pain endpoints. Because the metabolic and sensory measurements are collected in the same animals, a candidate's effect on glucose handling and on neuropathy can be read together.
Ahead of all three models sits an in vitro neurodegeneration assay. Neurons conditioned with high glucose for five days show reduced neurite area and the appearance of blebs, scored as a neurodegeneration index, and multiple test groups can be run in one experiment. It is used to screen compounds designed for neuroprotection before committing to an in vivo design.
The three models answer different questions. Streptozotocin gives a rapid type I substrate with the fullest set of reference compound data. High fat diet gives a diet driven insulin resistant substrate with a stable hypersensitive window. ZDF gives spontaneous obese type II diabetes with metabolic and sensory endpoints in the same animals. Across them, MD Biosciences applies a common endpoint platform of von Frey and thermal testing, intraepidermal nerve fiber staining by anti-PGP9.5 or immunohistochemistry, electrophysiology spanning conduction velocity and evoked potentials, and cytokine analysis in plasma and cerebrospinal fluid. The in vitro assay is available as a first pass.
Study design conversations are welcome at neuro@mdbiosciences.com.